Myeloid growth factors, particularly granulocyte macrophage-colony stimulating factor (GM-CSF), have the potential to worsen CRS symptoms and are not recommended during the first 3 weeks after tisagenlecleucel infusion or until CRS has resolved (1, 29). This evidence concerns the gene CSF2 and congenital rubella syndrome.